Use your antibodies-online credentials, if available.
No Products on your Comparison List.
Your basket is empty.
Find out more
Show all species
Show all synonyms
Select your species and application
anti-Rat (Rattus) MAP2K2 Antibodies:
anti-Human MAP2K2 Antibodies:
anti-Mouse (Murine) MAP2K2 Antibodies:
Go to our pre-filtered search.
Human Polyclonal MAP2K2 Primary Antibody for IF, WB - ABIN1882178
Burroughs, Oh, Barrett, DiAugustine et al.: Phosphatidylinositol 3-kinase and mek1/2 are necessary for insulin-like growth factor-I-induced vascular endothelial growth factor synthesis in prostate epithelial cells: a role for hypoxia-inducible ... in Molecular cancer research : MCR 2003
Show all 5 Pubmed References
Human Polyclonal MAP2K2 Primary Antibody for IHC (p), WB - ABIN1881526
Tran, Maurer, Nagamine: Stabilization of urokinase and urokinase receptor mRNAs by HuR is linked to its cytoplasmic accumulation induced by activated mitogen-activated protein kinase-activated protein kinase 2. in Molecular and cellular biology 2003
Show all 5 Pubmed References
Data show that SAM and SH3 domain containing 1 (show SASH1 Antibodies) protein (SASH1 (show SASH1 Antibodies)) binds with mitogen-activated protein kinase kinase 2 (MAP2K2), and SASH1 (show SASH1 Antibodies) mutations promote binding between SASH1 (show SASH1 Antibodies) and MAP2K2.
findings demonstrate the interaction of tRNA with MEK2 in pancreatic cancer cells and suggest that tRNA may impact MEK2 activity in cancer cells
Report a synthetic lethal interaction of cetuximab in combination with MEK1 (show MAP2K1 Antibodies)/2 inhibition for the NRAS (show NRAS Antibodies) mutant subgroup of metastatic colorectal cancer.
There are no other biomarkers correlated with treatment responses following MEK1 (show MAP2K1 Antibodies)/2 inhibition.
MEK2 was essential for the phosphorylation of MKK3 (show MAP2K3 Antibodies)/MKK6 (show MAP2K6 Antibodies) and p38 MAPK (show MAPK14 Antibodies) that directly impacted on cyclin D1 (show CCND1 Antibodies) expression.
High MEK2 expression is associated with inflammation.
there were significant decreases in intercellular adhesion molecules 1 (ICAM1 (show ICAM1 Antibodies)), ezrin (EZR (show EZR Antibodies)), mitogen-activated protein kinase kinase 2 (MAP2K2), and nitric oxide synthase (show NOS Antibodies) 3 (NOS3 (show NANOS3 Antibodies)) gene expressions in metabolic syndrome patients.
The patient showed a paternally inherited 16p13.11 microduplication and a de novo 19p13.3 microdeletion involving the mitogen-activated protein kinase kinase 2 gene (MAP2K2), in which mutations cause the cardio-facio-cutaneous (CFC (show PTPN11 Antibodies)) syndrome
Data show that mitogen-activated protein kinase (show MAPK1 Antibodies) kinases MEK1 (show MAP2K1 Antibodies)/2 inhibitor pimasertib (MEKI) sensitized the cells to apoptosis through its ability to promote a G1 cell cycle arrest.
the purpose of this paper was to investigate MAPK (show MAPK1 Antibodies) downstream signalling molecules in Natural killer cell phenotypes from Chronic Fatigue Syndrome/Myalgic Encephalomyelitis patients.
data suggest that, although short-term suppression of Mek1 (show MAP2K1 Antibodies)/2 in ES cells helps to maintain an inner cell mass-like epigenetic state, prolonged suppression results in irreversible changes that compromise their developmental potential
Erk5 (show MAPK7 Antibodies) MAP kinase (show MAPK1 Antibodies) is activated in response to PDGF (show PDGFA Antibodies)-BB in the smooth muscle cell line MOVAS in a manner dependent on Mekk2 (show MAP3K2 Antibodies), Mek1 (show MAP2K1 Antibodies)/2, Mek5 (show MAP2K5 Antibodies), PI3-kinase (show PIK3CA Antibodies) and protein kinase C (PKC (show PKC Antibodies)).
fluid shear stress induces autocrine TGF-beta (show TGFB1 Antibodies)/ALK5 (show TGFBR1 Antibodies)-induced target gene expression in renal epithelial cells, which is partially restrained by MEK1 (show MAP2K1 Antibodies)/2-mediated signaling.
FGF2 (show FGF2 Antibodies) is an extracellular inducer of COUP-TFII (show NR2F2 Antibodies) expression and may suppress the osteogenic potential of mesenchymal cells by inducing COUP-TFII (show NR2F2 Antibodies) expression prior to the onset of osteogenic differentiation
REDD1 (show DDIT4 Antibodies) is required for normal insulin (show INS Antibodies)-stimulated signaling, and a subtle balance exists between MEK1 (show MAP2K1 Antibodies)/2, REDD1 (show DDIT4 Antibodies), and mTOR (show FRAP1 Antibodies)
MEK1 (show MAP2K1 Antibodies) and MEK2 can substitute for each other but a minimum amount of MEK (show MDK Antibodies) is critical for placenta development and embryo survival
MK2 (show KCNA2 Antibodies)/3 cascade plays a strategic role in controlling synaptic plasticity and cognition.
MK2 (show KCNA2 Antibodies) attenuates dendritic cell-mediated Th1 (show HAND1 Antibodies) differentiation and autoimmune encephalomyelitis.
analysis of p38 (show CRK Antibodies)-MK2 (show KCNA2 Antibodies)-activated Rsk (show RPS6KA1 Antibodies) signaling in toll (show TLR4 Antibodies)-like receptor-stimulated dendritic cells
both MEK1 (show MAP2K1 Antibodies) and MEK2 have crucial roles in the integration of mesenchymal and epithelial signals essential for the development of the entire respiratory tract
the AtMKK2-AtMPK10 (show MAPK10 Antibodies) MAPK (show MAPK1 Antibodies) module regulates leaf venation complexity by altering polar auxin transport efficiency
Treatment of Arabidopsis with a membrane rigidifier, DMSO, causes MPK4 (show MAPK4 Antibodies) activation concomitantly with MEKK1 (show MAP3K1 Antibodies) and MKK2 phosphorylation.
Ca(2 (show CA2 Antibodies)+) signaling occurred upstream of the MEKK1 (show MAP3K1 Antibodies)-MKK2 pathway. MEKK1 (show MAP3K1 Antibodies) was phosphorylated by calcium/calmodulin-regulated receptor-like kinase (CRLK1), which suggested that CRLK1 is one of candidates located upstream of MEKK1 (show MAP3K1 Antibodies).
Data indicate that MEKK2 (show MAP3K2 Antibodies) is required for the mekk1 (show MAP3K1 Antibodies), mkk1 (show MAP2K1 Antibodies) mkk2, and mpk4 (show MAPK4 Antibodies) autoimmune phenotypes.
Data suggest that the MEKK1 (show MAP3K1 Antibodies)-MKK1 (show MAP2K1 Antibodies)/MKK2-MPK4 (show MAPK4 Antibodies) kinase cascade negatively regulates MEKK2 (show MAP3K2 Antibodies) and activation of MEKK2 (show MAP3K2 Antibodies) triggers SUMM2-mediated immune responses.
Data indicate that MKK2 plays a role in abiotic stress tolerance and plant disease resistance.
double loss-of-function mutant (mkk1 (show MAP2K1 Antibodies)/2) of MKK1 (show MAP2K1 Antibodies) and MKK2 is shown to have marked phenotypes in development and disease
Activation of MPK4 (show MAPK4 Antibodies) by flg22 is impaired in the mkk1 (show MAP2K1 Antibodies) mkk2 double mutants, suggesting that MKK1 (show MAP2K1 Antibodies) and MKK2 function together with MPK4 (show MAPK4 Antibodies) and MEKK1 (show MAP3K1 Antibodies) in a MAP kinase (show MAPK1 Antibodies) cascade to negatively regulate innate immune responses in plants.
The protein encoded by this gene is a dual specificity protein kinase that belongs to the MAP kinase kinase family. This kinase is known to play a critical role in mitogen growth factor signal transduction. It phosphorylates and thus activates MAPK1/ERK2 and MAPK2/ERK3. The activation of this kinase itself is dependent on the Ser/Thr phosphorylation by MAP kinase kinase kinases. Mutations in this gene cause cardiofaciocutaneous syndrome (CFC syndrome), a disease characterized by heart defects, mental retardation, and distinctive facial features similar to those found in Noonan syndrome. The inhibition or degradation of this kinase is also found to be involved in the pathogenesis of Yersinia and anthrax. A pseudogene, which is located on chromosome 7, has been identified for this gene.
ERK activator kinase 2
, MAP kinase kinase 2
, MAPK/ERK kinase 2
, MAPKK 2
, MEK 2
, dual specificity mitogen-activated protein kinase kinase 2
, mitogen-activated protein kinase kinase 2, p45
, MAP kinase/Erk kinase
, mitogen activated protein kinase kinase 2
, protein kinase, mitogen activated, kinase 2, p45
, dual specificity mitogen activated protein kinase kinase 2
, mitogen-activated protein kinase kinase type 2